Outcome of T-Lymphoblastic Leukemia-Lymphoma with Hyper C-VAD Regimen

Background: T-cell lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) are aggressive diseases with dismal prognoses. Materials and Methods: All adult patients with T-ALL and T-LBL who were candidates for the Hyper-CVAD chemotherapy protocol were included. We evaluated overall survival and progression-free survival in 46 new cases. The T-ALL and T-LBL number of cases was 32 and 14, respectively. Results: Two- and 3-year OS were 41.8% (standard error (SE): 7%) and 27.8% (SE: 7%), respectively. Two- and 3-year PFS were 36.9% (SE: 7%) and 25.3% (SE: 7%), respectively. The only variable that had a significant relationship with the duration of PFS and OS was Allogenic SCT. Patients receiving Allogeneic SCT had longer survival time (2-year overall survival of 80% against 20%) (p˂0.001). Conclusion:  These data support the concept that Hyper-CVAD is not an appropriate and adequate regimen. We need new targeted agents in the T-ALL and T-LBL induction regimen while considering Allogeneic SCT as a Consolidation.